<?xml-model href='http://www.tei-c.org/release/xml/tei/custom/schema/relaxng/tei_all.rng' schematypens='http://relaxng.org/ns/structure/1.0'?><TEI xmlns="http://www.tei-c.org/ns/1.0">
	<teiHeader>
		<fileDesc>
			<titleStmt><title level='a'>Absolute Quantitation of Phosphopeptides and Glycopeptides Using Coulometric Mass Spectrometry</title></titleStmt>
			<publicationStmt>
				<publisher>ACS</publisher>
				<date>08/20/2025</date>
			</publicationStmt>
			<sourceDesc>
				<bibl> 
					<idno type="par_id">10635266</idno>
					<idno type="doi">10.1021/acsmeasuresciau.5c00047</idno>
					<title level='j'>ACS Measurement Science Au</title>
<idno>2694-250X</idno>
<biblScope unit="volume">5</biblScope>
<biblScope unit="issue">4</biblScope>					

					<author>Md Tanim-Al Hassan</author><author>Yongling Ai</author><author>Bhavya Deshaboina</author><author>Timothy Yaroshuk</author><author>Arjun Sharma</author><author>Quentin Young</author><author>Howard D Dewald</author><author>Hao Chen</author>
				</bibl>
			</sourceDesc>
		</fileDesc>
		<profileDesc>
			<abstract><ab><![CDATA[Phosphorylation and glycosylation are two important protein post-transitional modifications (PTMs). However, quantification of these PTMs is challenging due to the lack of protein or peptide standards. In this study we introduced a novel approach using coulometric mass spectrometry (CMS) for absolute quantitation of phosphopeptides and glycopeptides without using standards. First, phosphorylated tyrosine peptides such as TSTEPQpYQPGENL and RRLIEDAEpYAARG can be converted into electrochemically active tyrosine peptides via enzymatic phosphate removal using alkaline phosphatase, prior to CMS quantitation. Accurate quantitation was obtained with small quantitation errors (0.3-6.6%). Alternatively, for electrochemically inactive phosphopeptides and glycopeptides, derivatization of their N-termini with an NHS ester reagent, 2,5-dioxo-1-pyrrolidinyl 3,4-dihydroxybenzene propanoate (DPDP), was conducted to introduce one electroactive catechol tag, allowing the DPDP-derivatized peptides to be quantified by CMS. This strategy was first validated using peptides RGD, GGYR, phosphopeptide RRApSVA and glycopeptide NYIVGQPSS(β-GlcNAc)TGNL-OH and successful quantification was achieved with quantification errors less than 6%. Taking one step further, we applied this approach to quantify glycopeptides generated from tryptic digestion of NIST monoclonal antibody (mAb). Through HILIC column separation, five N297 glycopeptides were successfully derivatized, separated and quantified by CMS without the use of standards. Due to the biological significance of PTMs, this study for quantifying peptides carrying PTMs would have a high potential for quantitative proteomics and biological research.]]></ab></abstract>
		</profileDesc>
	</teiHeader>
	<text><body xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Phosphorylation and glycosylation are among the most common and extensively studied post-translational modifications (PTMs). <ref type="bibr">[1]</ref><ref type="bibr">[2]</ref><ref type="bibr">[3]</ref><ref type="bibr">[4]</ref><ref type="bibr">[5]</ref><ref type="bibr">[6]</ref><ref type="bibr">[7]</ref> About 30% of the human proteome is phosphorylated, and phosphoprotein may exist as multiple phosphorylated forms. <ref type="bibr">8</ref> There are two main kinds of phosphorylation: O-phosphorylation, which occurs on serine, threonine, and tyrosine residues; and N-phosphorylation, which takes places on histidine, arginine, and lysine. <ref type="bibr">9</ref> Glycosylation plays various roles in the structure and function of proteins, and alterations in lycosylation could lead to numerous diseases including cancer and immune system deficiencies. <ref type="bibr">[10]</ref><ref type="bibr">[11]</ref><ref type="bibr">[12]</ref> N-glycosylation occurs mainly at asparagine (Asn or N) residues where the consensus tripeptide sequence NXS/T is located (where X is any amino acid except proline). At least one N-glycosylation motif is present in two-thirds of all human proteins, and ca. 50% of all human proteins are N-glycosylated. Other types of glycosylation include O-glycosylation, which occurs in the serine and threonine residues, and C-glycosylation which bonds on the indole rings of the tryptophan residues. <ref type="bibr">13,</ref><ref type="bibr">14</ref> In proteomics research, quantitative information of peptides and proteins is critical for helping us to understand biological processes. Quantification in mass spectrometry (MS)-based proteomics research relies on two fundamental strategies: relative and absolute quantitation. <ref type="bibr">[15]</ref><ref type="bibr">[16]</ref><ref type="bibr">[17]</ref><ref type="bibr">[18]</ref><ref type="bibr">[19]</ref> Relative quantitation methods involve comparing the levels of peptides or proteins among different samples. <ref type="bibr">20</ref> Traditionally label-free approach involves analyzing samples and comparing their mass spectra to determine peptide abundances relative to another sample. <ref type="bibr">21,</ref><ref type="bibr">22</ref> Alternatively, isotopic labeling is commonly used in relative quantitation, where peptides from two samples are labeled with heavy and light isotopes. <ref type="bibr">23,</ref><ref type="bibr">24</ref> The intensities of these labeled peptides are then compared to discern changes in abundance between the samples. <ref type="bibr">23,</ref><ref type="bibr">[25]</ref><ref type="bibr">[26]</ref><ref type="bibr">[27]</ref> Elegant approaches like tandem mass tag (TMT), isotope-coded affinity tags (ICAT), stable isotope labeling by amino acids in cell culture (SILAC), isobaric tags for relative and absolute quantitation (iTRAQ), metal element chelated tags (MECT), isotope-coded protein labeling (ICPL), and N, N-dimethyl leucine (DiLeu) isobaric tag methods fall under this category. <ref type="bibr">[28]</ref><ref type="bibr">[29]</ref><ref type="bibr">[30]</ref><ref type="bibr">[31]</ref><ref type="bibr">[32]</ref><ref type="bibr">[33]</ref><ref type="bibr">[34]</ref><ref type="bibr">[35]</ref><ref type="bibr">[36]</ref> Likewise, absolute quantitation of proteins involves spiking a known quantity of isotope-labeled target peptide into an experimental sample, followed by LC-MS or LC-MS/MS analysis. <ref type="bibr">18,</ref><ref type="bibr">21,</ref><ref type="bibr">[37]</ref><ref type="bibr">[38]</ref><ref type="bibr">[39]</ref><ref type="bibr">[40]</ref><ref type="bibr">[41]</ref><ref type="bibr">[42]</ref><ref type="bibr">[43]</ref><ref type="bibr">[44]</ref><ref type="bibr">[45]</ref><ref type="bibr">[46]</ref><ref type="bibr">[47]</ref><ref type="bibr">[48]</ref><ref type="bibr">[49]</ref> The three most well-known methods for absolute quantitation are absolute quantification (AQUA), quantification conCATamer (QconCAT) and protein standard absolute quantification (PSAQ). <ref type="bibr">17</ref> While these elegant techniques offer the advantage of determining the absolute amounts of target peptides across different samples, the necessity for using standard or isotope-labeled peptides poses challenges. These standard peptides may not always be readily available, and their synthesis can be expensive and time-consuming. <ref type="bibr">18,</ref><ref type="bibr">19,</ref><ref type="bibr">22</ref> Thus, the quest for a standard-free absolute quantitation method remains an ideal goal in the field of proteomics research. This is particularly true for quantifying protein PTMs such as phosphorylation and glycosylation in which the standard phosphopeptides or glycopeptides may be even more difficult to obtain.</p><p>Recently, we developed coulometric mass spectrometry (CMS) for absolute quantitation of electroactive analytes, using liquid chromatography/electrochemistry/mass spectrometry (LC/EC/MS) apparatus (illustrated in Figure <ref type="figure">S1</ref>). <ref type="bibr">[15]</ref><ref type="bibr">[16]</ref><ref type="bibr">[17]</ref><ref type="bibr">[18]</ref><ref type="bibr">[19]</ref><ref type="bibr">[50]</ref><ref type="bibr">[51]</ref><ref type="bibr">[52]</ref><ref type="bibr">[53]</ref> The method is based on electrochemical oxidation/reduction of analytes followed by MS to measure the oxidation/reduction yield.</p><p>Electrochemical reaction results in an electric current response, which can be integrated over time to calculate the electric charge Q involved in the redox reaction. According to Faraday's Law, Q is proportional to quantity of the oxidized/reduced analyte: Q = nzF, where n is the moles of the oxidized/reduced analyte, z is the number of electrons transferred per molecule during the redox reaction, and F is the Faraday's constant (9.65 &#215; 10 4 C/mol). Therefore, the moles of the oxidized/reduced analyte can be calculated as n = Q/zF. Meanwhile, upon oxidation or reduction, the target analyte shows a reduced intensity in the acquired MS spectra, and the relative analyte ion intensity change &#916;i, reflects the redox conversion yield. Thus, the moles of the oxidized/reduced analyte, in combination with the conversion yield, can be used to calculate the total amount of the analyte. In other words, Total amount of the analyte = (amount of the oxidized/reduced analyte)/(the conversion yield) = (amount of the oxidized/reduced analyte)/(the conversion yield)</p><p>With this CMS method, we conducted absolute quantitation of peptides and proteins based on electrochemical oxidation of oxidizable cysteine, tyrosine and tryptophan residues. <ref type="bibr">[15]</ref><ref type="bibr">[16]</ref><ref type="bibr">[17]</ref><ref type="bibr">[18]</ref><ref type="bibr">[19]</ref><ref type="bibr">[50]</ref><ref type="bibr">[51]</ref><ref type="bibr">[52]</ref><ref type="bibr">[53]</ref> For peptides without oxidizable residues, they could be derivatized to carry an electrochemical tag such as methylene blue, <ref type="bibr">17</ref> allowing them to be quantifiable by CMS after derivatization. In this study, we extended the CMS quantitation approach for peptides with PTMs such as phosphopeptides and glycopeptides. For phosphorylated tyrosine peptides, their phosphates were removed enzymatically to generate electroactive tyrosine peptides (Scheme 1a), before CMS quantitation. Alternatively, for electrochemically non-active phosphopeptides or glycopeptides, peptide derivatization with DPDP (Scheme 1b) was performed to introduce one electroactive catechol tag, prior to CMS quantitation. Upon electrochemical oxidation at a low oxidation potential (0.7 V vs. Ag/AgCl), the catechol tag tends to lose two protons and two electrons to form a quinone product (z=2, Scheme 1b), facilitating CMS quantitation. Using these strategies, several phosphopeptides, glycopeptides as well as glycopeptides from NIST mAb digest were successfully quantified, without using standards. Experimental Section Chemicals N-terminal protected amino acid BOC-Lys-OH, Gly-Gly-Tyr-Arg (GGYR, HPLC grade), Arg-Gly-Asp (RGD, HPLC grade), and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer were purchased from Sigma-Aldrich (St. Louis, MO). Phosphorylated RRApSVA (HPLC grade) was obtained from EMD Millipore (Temecula, CA). RRLIEDAEpYAARG, TSTEPQpYQPGENL, alkaline phosphatase (1 KU) from bovine intestinal mucosa and NIST mAb antibody were bought from Sigma-Aldrich (St. Louis, MO). NYIVGQPSS(&#946;-GlcNAc)TGNL-OH was purchased from Sussex Research (ON, Canada). 2,5-Dioxo-1-pyrrolidinyl 3,4dihydroxybenzene propanoate (DPDP) was bought from Aquila pharmatech LLC (Waterville, OH). Trypsin (sequencing grade) was purchased from Promega (Madison, WI). Dithiothreitol (DTT), iodoacetamide (IAA), ammonium bicarbonate (ABC) and sodium hydroxide were procured from Fisher Chemical (Fair Lawn, NJ). Formic acid (FA) and acetonitrile were 2e -, 2H + Peptide DPDP Derivatized peptide Electrochemical oxidation Oxidation product (CMS) a) b) PTM Catechol tag</p><p>obtained from Fisher Chemical (Fair Lawn, NJ), and deionized water used for sample preparation was obtained using a Millipore purification system (Burlington, MA).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Instrument</head><p>Our CMS system (apparatus shown in Figure <ref type="figure">S1</ref>) consisted of liquid chromatography (LC), electrochemistry (EC) and mass spectrometry (MS). Basically, an ultraperformance liquid chromatography (UPLC, Waters, Milford, MA) was connected with an electrochemical thin-layer flow cell equipped with either glassy carbon electrode (GCD, 6 mm ID) or boron-doped diamond electrode (BDD, 8 mm ID) as the working electrode (WE). The flow cell was further coupled with a high-resolution Orbitrap Q Exactive mass spectrometer (Thermo Scientific, San Jose, CA). An Ag/AgCl (3 M NaCl) electrode (RE, catalog no. MW-2021) was employed as a reference electrode (RE), while the stainless-steel body of the cell functioned as the counter electrode (CE).</p><p>Separation of peptides was achieved using either an Agilent poroshell reversed-phase column (HPH-C18, 2.1 mm &#215; 100 mm, 1.9 &#956;m, Agilent, Santa Clara, CA), reversed-phase column (BEH C18, 2.1 mm &#215; 100 mm, 1.7 &#956;m) or hydrophilic interaction liquid chromatography (HILIC) column (HALO Penta HILIC column, 2.1 mm &#215; 250 mm; 2.7 &#956;m, used for the separation of NIST mAb glycopeptides). The mobile phase flow rate was set at 0.2-0.3 mL/min. Mobile phase A used was water with 0.1 % FA and mobile phase B was acetonitrile with 0.1 % FA.</p><p>OriginPro 2018b was used to import and integrate the recorded electric current peak to calculate the total electric charge of Q. The peptide flowing out of electrochemical cell was online analyzed using the Orbitrap mass spectrometer equipped with a heated electrospray ionization (HESI) source with the following parameters: sheath gas flow rate, 35; auxiliary gas flow rate, 10; spray voltage, 3.0 kV; sweep gas flow rate, 0; capillary temperature, 300 &#176;C; auxiliary gas heater temperature, 100 &#176;C; S-lens RF level, 50. Mass spectra were acquired by Thermo Xcalibur (3.0.63). Before each use, the glassy carbon working electrode underwent thorough cleaning by polishing with alumina slurry. In situ cleaning involved applying alternative positive and negative potentials of +2.0 V and -2.0 V was used for BDD electrode.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cyclic voltammetry (CV) experiment</head><p>We first derivatized the GGYR peptide using DPDP and isolated the derivatized peptide, denoted as *GGYR (* represents the derivatized peptide) via fractionation by Shimadzu LC (LC 40B XR). Using a homemade undivided cell, we utilized 20 mL of 200 &#181;M intact GGYR or 30 &#181;M of *GGYR for the CV experiments conducted in a H2O: ACN: FA (70:30:1). A 3 mm GCE electrode (GCE) with an area of 0.07 cm 2 served as the WE, while an Ag/AgCl reference electrode was positioned in close proximity to the WE to regulate the potential. Additionally, a carbon cloth of 5 cm 2 size was positioned opposite to the WE, serving as the CE. Monitoring and recording of the oxidation current were facilitated by an Epsilon EClipse&#8482; potentiostat (BASi, West Lafayette, IN, USA).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Alkaline Phosphatase Treatment</head><p>Phosphatase was dissolved in 1 mL of 10 mM tris-HCL (pH 8.0) containing 1 mM magnesium chloride and then stored in fridge (4 o C). 50 &#956;L of RRLIEDAEpYAARG (1 mM) or 100 &#956;L of TSTEPQpYQPGENL (0.5 mM) was mixed with 20 &#956;L alkaline phosphatase (0.86 KU/mL) respectively and incubated at 37&#176;C for 1 h. Formic acid was added (final formic acid concentration: 1% by volume) after the dephosphorylation reaction. The sample was cooled to room temperature and diluted with 0.1% FA to final concentration of 1.0 &#956;M for CMS analysis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protein digestion</head><p>A 40 &#181;L of 10 &#181;g/1&#181;L (400 &#956;g) of NIST mAb (Ref: 8671) was denatured using 80 &#956;L of 8 M urea at room temperature and then vortexed for 15 min. 5 &#956;L of 1 M DTT (freshly prepared) was added to the sample and then shaken for 1 h at 37 &#176;C in a water bath. A 20 &#956;L of 500 mM IAA was then added to the sample at room temperature in the dark for 30 min. The sample mixture was then desalted and buffer exchanged with 50 mM ABC buffer by Amicon 10K molecular weight cut-off filter (MWCOF) and then digested overnight with 20 &#181;g trypsin (protein/trypsin ratio: 20:1).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Peptide derivatization with DPDP</head><p>For the proof-of-concept experiment, we first derivatized N-terminal protected amino acid BOC-Lys-OH with DPDP-NHS ester in 1:10 molar ratio using H2O: ACN (50:50) as a solvent with pH 8.3 adjusted by NaOH. The sample was derivatized for overnight reaction using mild dark vortex. The same derivatization condition was applied for peptides RGD, RRApSVA and NYIVGQPSS(&#946;-GlcNAc) TGNL-OH. To maintain a good buffering system for controlling pH and reduce reaction time, we also derivatized the GGYR peptide using 100 mM HEPES buffer (pH 8.3) and using a 1:10 molar ratio (peptide:DPDP) for the derivatization process.</p><p>For the derivatization of glycopeptides from mAb, the mAb digest sample was vacuum dried and reconstituted in 20 mM HEPES buffer (pH 8.5) to prepare a 5.3 &#181;M sample, which was then shake with DPDP (159 mM, 3000-fold in excess) overnight in the dark for derivatization. The sample was dried out and reconstituted in ACN/H2O (65:35 v/v) to prepare a 5.3 &#181;M derivatized sample. An underivatized sample was also prepared to assist the measurement of the glycopeptide derivatization yields. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>LC separation for CMS quantitation</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results and Discussion</head><p>The integration of mass spectrometry (MS) with electrochemistry (EC), namely EC/MS, has drawn considerable attention and found many applications, including drug metabolism study, protein structural analysis, and electrochemical reaction mechanism elucidation. <ref type="bibr">[54]</ref><ref type="bibr">[55]</ref><ref type="bibr">[56]</ref><ref type="bibr">[57]</ref><ref type="bibr">[58]</ref><ref type="bibr">[59]</ref> The method can also be used to capture elusive reaction intermediates <ref type="bibr">[60]</ref><ref type="bibr">[61]</ref><ref type="bibr">[62]</ref><ref type="bibr">[63]</ref><ref type="bibr">[64]</ref><ref type="bibr">[65]</ref><ref type="bibr">[66]</ref><ref type="bibr">[67]</ref><ref type="bibr">[68]</ref><ref type="bibr">[69]</ref> and enable electrosynthetic reaction screening. <ref type="bibr">[70]</ref><ref type="bibr">[71]</ref><ref type="bibr">[72]</ref> As a new application of the EC/MS technique, the unprecedented advantage of CMS is the capability of absolute quantitation without using any standards or establishing a calibration curve. In our previous research, we successfully demonstrated the capability of CMS to quantify peptides containing electroactive residues like cysteine, tyrosine and tryptophan. <ref type="bibr">[15]</ref><ref type="bibr">[16]</ref><ref type="bibr">[17]</ref><ref type="bibr">[18]</ref><ref type="bibr">[19]</ref><ref type="bibr">[50]</ref><ref type="bibr">[51]</ref><ref type="bibr">[52]</ref><ref type="bibr">[53]</ref> In this study, a similar CMS approach was adopted to quantify peptides containing phosphorylated tyrosine residues, after enzymatic removal of phosphate to generate electrochemically active tyrosine peptides. As the removal of phosphate by phosphatase is quantitative, the measured quantity of the resulting tyrosine peptide can reflect the amount of the phosphopeptide precursor.</p><p>On the other hand, in a more general approach, phosphopeptides or glycopeptides can be selectively derivatized by DPDP to carry an electrochemical tag of catechol (Scheme 1b), prior to CMS quantitation. In comparison to our previously used methylene blue tag, <ref type="bibr">17</ref> the catechol tag is more polar and water soluble, leading to better peptide separation by LC and therefore benefits CMS quantitation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CMS quantitation of phosphopeptides after phosphate removal</head><p>To explore the feasibility of CMS quantitation of phosphorylated tyrosine peptides, one standard peptide TSTEPQpYQPGENL was first tested. As shown in Figure <ref type="figure">1a</ref> and 1b, after incubation with alkaline phosphatase, the TSTEPQpYQPGENL was quantitatively <ref type="bibr">[73]</ref><ref type="bibr">[74]</ref><ref type="bibr">[75]</ref> converted into TSTEPQYQPGENL (the original peak of TSTEPQpYQPGENL at 3.2 min disappeared (Figure <ref type="figure">1a</ref>); instead, the product TSTEPQYQPGENL peak appeared at 3.5 min in the TIC diagram (Figure <ref type="figure">1b</ref>). When the intact TSTEPQpYQPGENL was injected, no electric current peak was observed with an applied of +1.05 V for oxidation (Figure <ref type="figure">1g</ref>), indicating that phosphorylated tyrosine is not electrochemically active. In contrast, after the injection of the dephosphorylated EICs of TSTEPQYQPGENL at m/z 731.84 were acquired e) when the cell was off and f) when the cell was turned on (applied potential: + 1.05 V). Electric current diagrams were collected from (g) TSTEPQpYQPGENL and (h) the oxidation of TSTEPQYQPGENL.</p><p>peptide TSTEPQYQPGENL sample, a sharp electric current peak was observed under the same oxidation conditions (Figure <ref type="figure">1h</ref>), which is in line with our previous observation of electrochemical oxidation of tyrosine-containing peptides. <ref type="bibr">19,</ref><ref type="bibr">53</ref> Indeed, it was further confirmed by the corresponding MS spectra recorded upon electrochemical oxidation (Figures <ref type="figure">1c</ref> and <ref type="figure">1d</ref>).</p><p>Compared to the MS spectrum (Figure <ref type="figure">1c</ref>) without electrolysis, the +2 ion of TSTEPQYQPGENL was observed at m/z 731.84, whereas a new peak at m/z 730.84 (Figure <ref type="figure">1d</ref>), corresponding to +2</p><p>e) Cell off Area=1.12E+9 f) Cell on Area=9.14E+8 Relative Abundance m/z Time (min) c) Cell off d) Cell on Time (min) Current (&#956;A) h) TSTEPQYQPGENL g) TSTEPQpYQPGENL Q= 3.79E-07 C Relative Abundance [TSTEPQYQPGENL-H+2H] 2+ 731.84 732.34 730.84 a) 732.84 733.35 Relative Abundance Time (min) 731.84 TIC, before dephosphorylation b) TIC, after dephosphoylation 732.34 732.84 733.35 TSTEPQpYQPGENL TSTEPQYQPGENL</p><p>ion of the oxidized peptide product and resulting from 2 electron and 2 proton losses upon tyrosine oxidation, <ref type="bibr">18,</ref><ref type="bibr">19,</ref><ref type="bibr">53</ref> was detected, when +1.05 V was applied to the cell for oxidation. The integrated EIC peak area of m/z 730.84 shown in Figure <ref type="figure">1f</ref> was reduced by 18.4% compared to the same peak in Figure <ref type="figure">1e</ref>, suggesting that the oxidation yield for TSTEPQYQPGENL was 18.4% (see detailed data in Table <ref type="table">S1</ref>). The amount of the oxidized TSTEPQYQPGENL was calculated to be 10.64 pmol, based on the integration of the current peak area shown in Figure <ref type="figure">1h</ref> and the oxidation yield using eq. 1. Therefore, the measured amount of TSTEPQYQPGENL was 10.64 pmol (Table <ref type="table">S1</ref>).</p><p>A triplicate measurement gave the average amount of TSTEPQYQPGENL to be 10.66 pmol, which turned out to be close to the theoretical amount of 10.0 pmol, with the measurement error of 6.6% (Table <ref type="table">S1</ref>).</p><p>RRLIEDAEpYAARG, another phosphopeptide that contains phosphotyrosine, was also analyzed in the same way by CMS. The RRLIEDAEpYAARG was also quantitatively converted into RRLIEDAEYAARG by phosphatase (Figure <ref type="figure">S2</ref>  <ref type="table">S2</ref>). The results shown above confirm that CMS can be used for absolute quantitation of phosphorylated tyrosine peptides, in combination with enzymatic phosphate removal.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CMS quantitation after derivatization</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quantitation of standard amino acid and peptides</head><p>In this study, we also developed an alternative CMS approach for quantifying phosphopeptides and glycopeptides, in combination with DPDP derivatization strategy. First, we tested some model peptides to validate the quantitation method and then applied it to quantify phosphopeptides and glycopeptides.</p><p>We initially chose N-terminal protected amino acid BOC-Lys-OH as a model compound for our investigation. We observed a 94% reaction efficiency for this amino acid, as evidenced by a decrease in the EIC peak area of the intact peptide ion at m/z 247.1 from 5.80E6 before DPDP derivatization to 3.44E5 after DPDP derivatization (shown in Figure <ref type="figure">S3</ref>). For CMS quantitation, we injected 5 &#956;L of 1 &#956;M BOC-Lys-OH after its derivatization (injection amount: 5.0 pmol).</p><p>Additionally, a minor potential of 0.  <ref type="table">S3</ref>). The total charge involved in peptide oxidation was determined to be 1.67E-07C through integration of the peptide oxidation current (Figure <ref type="figure">S4-f</ref>). According to eq. 1 and z = 2 for the oxidation of the catechol moiety, it was determined that the amount of BOC-Lys-OH by CMS was 4.4 pmol, after considering 94% derivatization yield. In triplicate measurements, the average value of the three runs was calculated to be 4.7 pmol (Table <ref type="table">S3</ref>). The theoretical amount of BOC-Lys-OH used for CMS quantification was 5.0 pmol. The quantitation error of BOC-Lys-OH was -5.4% (Table <ref type="table">S3</ref>), suggesting the quantitation feasibility of this alternative CMS approach.</p><p>Peptide RGD was then chosen as an additional test sample for CMS quantification method validation. A derivatization yield of 94% for this peptide using DPDP was measured using LC/MS in the similar way as described above for sample BOC-Lys-OH. Figure <ref type="figure">S5</ref>-a displays the +1 ion of the derivatized RGD (m/z 511.2) and its oxidized product (m/z 509.2, probably due to in-source oxidation). The EIC peak area of m/z 511.2 decreased by 10% following oxidation, indicating an oxidation yield of 10% (Figures <ref type="figure">S5c</ref> and <ref type="figure">S5d</ref>). The total charge Q during oxidation was recorded at 7.16E-8C. A theoretical 5.0 pmol of the peptide was injected, with an actual measured amount of 4.7 pmol (calculated based on eq. 1 with further consideration of the 94% derivatization yield, see details in Table <ref type="table">S4</ref>), reflecting a slight measurement error of -6%.</p><p>Another peptide GGRY was also selected and derivatized by DPDP for test, for the reason to show that the catechol tag can be selectively oxidized without oxidizing its tyrosine residue when the applied potential is low. In order to gain deeper insights into the oxidation properties of DPDP derivatized peptide, we conducted cyclic voltammetry (CV) of intact GGYR and the derivatized GGRY, *GGYR. *GGRY was obtained by the reaction of GGYR with DPDP followed by LC purification. A 20 mL of 200 &#181;M intact GGYR peptide (dissolved in H2O: ACN: FA, 70:30:1 by volume) was conducted for CV. Upon initiating the CV experiment with a positive scan from 0 mV to 1400 mV (vs. Ag/AgCl), a discernible peak (I) at a potential of 1050 mV corresponding to the oxidization of the tyrosine residue of GGYR was observed as shown in Figure <ref type="figure">2a</ref> (the observed onset oxidation potential for tyrosine is 900 mV). The oxidation of tyrosine at 1050 mV is consistent with our previous observation. <ref type="bibr">19</ref> In contrast, when CV of 20 mL of 30 &#181;M *GGYR (dissolved in H2O: ACN: FA, 70:30:1 by volume) was performed, two peaks (I &amp; II) were noticed, corresponding to the oxidation of tyrosine moiety of *GGYR at 1050 mV (peak I, Figure <ref type="figure">2b</ref>) and the oxidation of the catechol tag of *GGYR at 700 mV (the observed onset oxidation potential for the catechol tag is 620 mV, peak II, Figure <ref type="figure">2b</ref>), respectively. A background CV in H2O: ACN: FA Potential (mV) vs Ag/AgCl Current density (&#181;A/cm 2 ) -7 -5 -3 -1 1 3 0 350 700 1050 1400 b) *GGYR (II) (I) -90 -70 -50 -30 -10 10 30 0 350 700 1050 1400 a) GGYR (I) 613.0 614.5 616.0 617.5 619.0 0 50 100 0 50 100 616.2 614.2 617.2 618.2 616.2 614.2 617.2 618.2 5.8 6.1 6.4 6.7 7.0 Time (min) 0 20 40 60 5 6 7 8 9 10 Time (min) *GGYR Cell off EIC peak area: 6.39E5 e) Cell on EIC peak area: 5.93E5 f) Sample h) blank g) 5 10 15 20 25 8.1 8.2 8.3 8.4 8.5 6.0 6.2 6.4 6.6 6.8 Current (nA) Cell off c) [*GGYR-2H+H] + [*GGYR+H] +</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell on d) m/z</head><p>Relative abundance dash lines in Figure <ref type="figure">2a</ref> and 2b was also collected to separate faradic current from its non-faradic counterpart. From the CV plots shown in Figure <ref type="figure">2a</ref> and Figure <ref type="figure">2b</ref>, it was clear that the selective oxidation of the tag of the derivatized peptide without oxidizing the tyrosine residue can be achieved at a potential range between 620 and 900 mV. Therefore, in our experiment, 700 mV or 800 mV was selected as the oxidation potential for our CMS experiments. As it can be seen that our newly employed derivatizing agent DPDP offers a distinct advantage by undergoing oxidation at a lower potential of 0.7 V vs Ag/AgCl during CMS quantitation. This characteristic shows that it is less susceptible to the phenomenon of surface fouling on the electrode. Throughout our experimental endeavors, we observed a reduction in the frequency of electrode cleaning procedures.</p><p>In order to improve the efficiency of peptide derivatization using the DPDP reagent, 100 mM HEPES buffer (pH 8.3) was used as the buffer for GGYR derivatization and a 100% derivatization yield was achieved (no intact GGYR was seen after derivatization for 4 h), thus avoiding the necessity of measuring the derivatization yield. This process also significantly shortened the reaction time compared to the traditional overnight protocol. Subsequently, *GGRY was subject to CMS measurement. Before introducing the sample to the electrochemical cell, the first 3 minutes were diverted to waste to eliminate the HEPES buffer. When the cell was turned off, an ion of m/z 616.2 was observed (Figure <ref type="figure">2c</ref>), corresponding to the protonated *GGRY.</p><p>Another ion at m/z 614.2 was also seen (Figure <ref type="figure">2c</ref>), probably due to in-source oxidation. The integrated EIC peak area for m/z 616.2 decreased by 7.2% following oxidation (Figures <ref type="figure">2e</ref> and <ref type="figure">2f</ref>), indicating a peptide oxidation yield of 7.2%. The total oxidation charge (Q) was calculated as 6.92E-08 C (Figure <ref type="figure">2h</ref>). We injected an expected 5.0 pmol of peptide, with an actual measured amount of 4.7 pmol (triplicate measurements, Table <ref type="table">S5</ref>), yielding a small measurement error of -5.4%.</p><p>To verify that the oxidation did occur to the catechol tag located in the N-terminal of the *GGRY peptide, both the oxidized peptide product ion (m/z 614.2) and the intact peptide ion (m/z 616.2) were subject to MS/MS analysis. For this analysis, the *GGYR sample was introduced into the electrochemical cell for oxidation at 0.7 V using a syringe pump. The oxidation product was collected for analysis by nano-electrospray ionization, resulting in the detection of the oxidized G'GYR ion (' indicates the oxidized catechol tag) at m/z 614.2. As depicted in Figure <ref type="figure">S6</ref>, upon collision induced dissociation (CID), m/z 614.2 produced a fragment ion b2-2H (m/z 277.1), whereas the intact *GGYR ion (m/z 616.2) generated b2 (m/z 279.1), which is in line with the occurrence of oxidation to the N-terminal catechol tag of *GGYR indeed. Our method's quantitation sensitivity was also evaluated by investigating of CMS quantitation by injecting 6 &#181;L of 15 nM *GGYR sample (total amount: 150 fmol *GGYR). The integrated EIC peak area for m/z 616.2 decreased by 9.5% following oxidation (Figures <ref type="figure">S7c</ref> and <ref type="figure">7d</ref>), indicating a peptide oxidation yield of 9.5%. The total oxidation charge (Q) was calculated as 2.54E-09 C (Figure <ref type="figure">S7f</ref>). The actual measured amount of 146 fmol by CMS (triplicate measurements, Table <ref type="table">S6</ref>), showed a small measurement error of -3.0% in comparison with the theoretical injection amount of 150 fmol. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quantification of phosphopeptides/glycopeptides</head><p>After quantifying standard peptides, we applied the method to quantify phosphopeptides and glycopeptides, as demonstration of its application. A phosphorylated peptide, RRApSVA, was selected as a test sample that has no oxidizable amino acid residue. The derivatization yield of this peptide was determined to be 68% by comparing the EIC peak area of the intact peptide (m/z 739.4) signal before and after the derivatization reaction (Table <ref type="table">S7</ref>). Prior to oxidation, the +1 ion of derivatized RRAPSVA was detected at m/z 903.4 (Figure <ref type="figure">3a</ref>). An in-source oxidation peak was seen at m/z 901.4 (Figure <ref type="figure">3a</ref>) and its signal intensity increased after triggering the oxidation by applying 0.7 V (vs. Ag/AgCl) to the WE of the cell (Figure <ref type="figure">3b</ref>). In-source oxidation caused the measurement complexity due to an overlap of m/z 903.4 with the M+2 isotope peak of m/z 901.4.</p><p>To avoid this complexity, we selected the peak of m/z 904.4 to calculate the oxidation yield. Upon compared to before oxidation (Figure <ref type="figure">3c</ref>), indicating the oxidation yield of 5.5%. The total charge Q involved in the oxidation in this case was determined to be 3.65E-08C (Figure <ref type="figure">3f</ref>). This Q value, along with the oxidation yield (i.e., eq. 1), was utilized to calculate the quantity of the derivatized peptide to be 3.43 pmol (Table <ref type="table">S7</ref>). Considering the 68% derivatization yield, the total peptide amount was calculated to be 5.0 pmol. Triplicate measurements gave an averaged peptide amount of 5.2 pmol (Table <ref type="table">S7</ref>). Once again, this value aligns well with the theoretical peptide amount of 5 pmol, with a small quantitation error of 3.4% (Table <ref type="table">S7</ref>).</p><p>To investigate the CMS quantification method for glycopeptide analysis, A glycosylated peptide, NYIVGQPSS(&#946;-GlcNAc)TGNL-OH, was selected for testing. The derivatization yield of</p><p>7.0 8.5 10.0 11.5 857.0 859.0 861.0 0 50 100 0 50 100 Relative abundance m/z Time (min) Time (min) Area = 7.05E6 Area = 6.68E6 Cell off Cell on a) Cell off b) Cell on [M+2H] 2+ 858.9 [M-2H+2H] 2+ 859.4 859.9 860.4 860.9 857.4 857.9 858.9 859.4 859.9 860.4 860.9 857.4 857.9 c) d) f) Oxidation current 20 28 11.2 11.5 11.8 8.9 9.2 9.5 40 80 120 10.8 e) Current (nA) *NYIVGQPSS(&#946;-GlcNAc)TGNL-OH</p><p>this peptide was determined to be 98% by comparing the EIC peak area of the intact peptide (m/z 776.9) signal before and after the derivatization reaction (Table <ref type="table">S8</ref>). The derivatized peptide was then measured using CMS. Before oxidation, the +1 ion of *NYIVGQPSS(&#946;-GlcNAc)TGNL-OH was detected at m/z 858.9 (Figure <ref type="figure">4a</ref>) and its isotope peak at m/z 859.9 was used for calculation of the oxidation yield. Upon peptide oxidation, the intensity at m/z 859.9 decreased by 5.3% after oxidation (Figure <ref type="figure">4d</ref>) compared to no oxidation (Figure <ref type="figure">4c</ref>), indicating the peptide oxidation yield of 5.3%. The total charge Q involved in the oxidation in this case was determined to be 5.2E-08C</p><p>(Figure <ref type="figure">4f</ref>). This Q value, along with the oxidation yield, was utilized to calculate the quantity of the derivatized peptide to be 5.13 pmol. Considering the 98% derivatization yield, the total averaged peptide amount was calculated to be 5.25 pmol (Table <ref type="table">S8</ref>). Once again, this value aligns well with the theoretical peptide amount of 5 pmol, with a small quantitation error of 5.0%.</p><p>As shown above, several peptides including phosphopeptides and glycopeptides were tested in this study and the quantitation errors were good and within &#177;7%. The results are summarized in Table <ref type="table">1</ref>. The results suggest the feasibility and accuracy of our CMS for quantitation.</p><p>Table <ref type="table">1</ref>. Summary of CMS quantitation results for the measured peptides </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quantitation of glycopeptides from IgG</head><p>As a demonstration of the application of our CMS approach, we applied it for quantifying glycopeptides of antibody IgG. MS techniques for antibody quantification in biotherapeutics typically employ a "bottom-up" strategy, in which proteins are enzymatically digested into peptides. However, quantitation of N-glycosylation is a challenging task. The lack of commercially available N-glycosylated standards precludes absolute quantitation, and thus, relative quantitation of glycosylation is performed by multiple reaction monitoring (MRM) method where relative comparisons of glycan/glycopeptide signals are taken into account. <ref type="bibr">76</ref> In our study, using CMS after peptide derivatization, we enabled standard-free quantification of several glycopeptides originating from the heavy chain Fc of the IgG (located on the residue N297, see the sequence information of NIST monoclonal antibody (mAb) in SI). A 10 12 14 16 18 20 22 24 26 28 30 32 34 0 50 100 0 50 100 0 50 100 0 50 100 0 50 100 19.83 20.36 22.37 25.03 27.45</p><p>HILIC column was used for the separation of these glycopeptides due to the high affinity of the glycopeptides. <ref type="bibr">77</ref> Previously we reported NIST mAb glycopeptide quantitation by CMS but the direct electrochemical oxidation of those glycopeptides was complicated, due to the presence of two oxidizable tyrosine residues in them. <ref type="bibr">53</ref> As the oxidation of one or both of the tyrosine residues occurred, the CMS quantitation required the assumption that the oxidation product resulting from one tyrosine oxidation has the same ionization efficiency as the oxidation product resulting from oxidation of two tyrosine residues, making the calculation not straightforward. In this study, we took the protocol to derivatize these glycopeptides with DPDP, so the oxidation at a low oxidation potential of 0.8 V could selectively occur to the catechol tags of the derivatized glycopeptides rather than the tyrosine residues, thus simplifying the quantitation calculation.</p><p>In our study, the NIST mAb was subjected to trypsin digestion, from which five glycopeptides (each with glycosylation at the N297 residue of the Fc heavy chain), EEQYNSTYR-G0F, EEQYNSTYR-G1F, EEQYNSTYR-G2F, EEQYNSTYR-G1F(-GlcNAc), and EEQYNSTYR-G2F(Hex) (structures shown in Table <ref type="table">2</ref>) were identified. The glycopeptides were derivatized using DPDP, and the derivatization yields were found to be 93-98% (Table <ref type="table">S8</ref>).</p><p>Subsequently, the derivatized glycopeptides were separated by a HILIC column and their EICs are shown in Figure <ref type="figure">5a</ref>. The major glycoforms detected were *EEQYNSTYR-G0F, *EEQYNSTYR-G1F, and *EEQYNSTYR-G2F based on observed EIC peak intensities, while minor glycoforms included *EEQYNSTYR-G1F(-GlcNAc) and *EEQYNSTYR-G2F(Hex). It is noteworthy that *EEQYNSTYR-G1F exhibited a split peak at 22.4 min (the 3 rd panel of Figure <ref type="figure">5a</ref>) due to partial separation of glycan isomers resulting from differences in galactose &#945;-3/6 linkage. <ref type="bibr">77</ref> Additionally, the glycopeptide *EEQYNSTYR-G1F(-GlcNAc) eluted at 20.4 min (the second panel of Figure <ref type="figure">5a</ref>), with an extra peak observed at 22.4 min most likely due to in-source fragmentation of the *EEQYNSTYR-G1F ion. The electric oxidation current peaks of these derivatized glycopeptides are shown in Figure <ref type="figure">5b</ref>.</p><p>Table 2. NIST mAb glycopeptides quantities measured by CMS a Structures using the Consortium for Functional Glycomics (CFG) Notation. Symbol representations of glycans: galactose = yellow circles, mannose = green circles, Nacetylglucosamine = blues boxes, fucose = red triangles. Glycopeptides Glycan structures a m/z of +2 ions of derivatized glycopeptides RT (min) Quantity measured by CMS (pmol) Quantity measured by CMS (%) Quantity measured by Zhao.et al., 79 (%) *EEQYNSTYR-G0F 1399.55025 19.83 31.3 29.5 38.4 *EEQYNSTYR-G1F (-GlcNAc) 1379.03697 20.36 0.9 0.8 1.7 *EEQYNSTYR-G1F 1480.57666 22.37 33.2 31.3 34.7 *EEQYNSTYR-G2F 1561.60307 25.03 6.2 5.9 7.4 *EEQYNSTYR-G2F(Hex) 1642.62948 27.45 1.3 1.2 3.5 Total amount 72.9 68.7 85.7</p><p>peak of m/z 1399.5, for the oxidation yield calculation. The oxidation yield for *EEQYNSTYR-G0F was determined to be 4.3% (Table <ref type="table">S9</ref>) based on the EIC peak area drop of m/z 1401.0 upon oxidation (Figures S8-g and S8-h). The oxidation current was recorded 2.86E-7C. According to eq. 1, the measured amount of *EEQYNSTYR-G0F was 29.4 pmol (triplicate measurements, Table <ref type="table">S9</ref>). Considering the 94% derivatization yield for this glycopeptide (Table <ref type="table">S9</ref>), the amount of EEQYNSTYR-G0F was found to be 31.3 pmol. Similar calculations were performed for *EEQYNSTYR-G1F, *EEQYNSTYR-G2F, *EEQYNSTYR-G1F(-GlcNAc), and *EEQYNSTYR-G2F(Hex), yielding the measured quantities of 33.2, 6.2, 0.9, and 1.3 pmol, respectively (See Table <ref type="table">S9</ref>, Figures <ref type="figure">S8</ref> and <ref type="figure">S9</ref>). These glycopeptide quantities were also calculated relative to the theoretical total amount of IgG glycopeptides, which was 106 pmol (10 &#956;L of 5.3 &#956;M IgG, totaling 53.0 pmol which would produce 106 pmol glycopeptides in total by considering that one IgG has two symmetrical heavy chain totals), and listed in Table <ref type="table">2</ref>. The summative amount of the five measured glycopeptides was 72.9 pmol, which is in reasonable agreement with the theoretical value of 106 pmol, with a discrepancy of approximately -31.3% (Table <ref type="table">2</ref>). This discrepancy likely arose from sample losses during sample preparation such as enzymatic digestion or from the presence of additional minor glycopeptides that were not quantified. <ref type="bibr">78</ref> Nevertheless, our CMS results thus provide an effective estimation of precursor glycoprotein quantity. Furthermore, our CMS results were compared with data from previous NIST mAb glycosylation studies by Zhao et al <ref type="bibr">79</ref> which involved relative quantification of glycosylated peptides based on MS peak areas. As presented in Table 2, the relative abundances of the three major glycopeptides (*EEQYNSTYR-G0F, *EEQYNSTYR-G1F and*EEQYNSTYR-G2F) determined by CMS were close to the value reported by Zhao et al., representing (29.5% vs. 38.4%), (31.3% vs. 34.7%) and (5.9% vs. 7.4%) of total antibody abundance, respectively. While the relative abundances determined by CMS and Zhao's method are similar, our CMS method uniquely</p><p>provides absolute quantification for each glycopeptide. These findings underscore the effectiveness and potential utility of CMS for precise glycopeptide quantification.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p>In this study, we demonstrated an absolute quantitation strategy for quantifying phosphopeptides and glycopeptides by using the coulometric mass spectrometry approach in combination with an electrochemical labelling technique. Standard peptides, phosphopeptides and glycopeptides were successfully quantified by CMS with good quantitation accuracy. We also quantified glycopeptides from digested IgG. By this approach we were able to estimate the amount of glycoprotein based on the abundances of surrogate glycopeptides. The highlight of CMS is that it does not require an isotope-labeled standard to achieve absolute quantity, which has the potential to break the bottleneck in many current methods. It can be seen that our method could be also applicable for quantifying peptides or proteins with other types of PTMs such as S-nitrosation, Nacetylation, methylation, or lipidation, which could contribute to quantitative proteomics.</p></div></body>
		</text>
</TEI>
